Genistein suppression of TNF-alpha-induced fractalkine expression in endothelial cells.
Cell. Physiol. Biochem. 2010
Mi Jeong Sung, Duk-Hoon Kim, Munkhtugs Davaatseren, Haeng Jeon Hur, Won Kim, Yu Jin Jung, Sung Kwang Park, Dae Young Kwon
Genistein is a polyphenolic nonsteroidal isoflavonoid with estrogen-like activity has been shown to have anticancer, antioxidant, and anti-inflammatory activities. Fractalkine is a unique chemokine that functions as a chemoattractant and an adhesion molecule on endothelial cells activated by proinflammatory cytokines. In this study, we investigated the effects of genistein (5-25 muM) on fractalkine expression in human umbilical vein endothelial cells (HUVECs) and on its receptor, CX3CR1, in THP-1 cells in response to treatment with tumor necrosis factor (TNF)- alpha. TNF-alpha significantly induced fractalkine expression in endothelial cells. Genistein decreased TNF-alpha-induced fractalkine expression through suppression of Akt and p38 phosphorylation and NF-kappaB activities. Genistein also strongly suppressed TNF-alpha-induced expression of CX3CR1 in monocytes. Genistein suppressed TNF-alpha-stimulated adhesion of monocytes to HUVECs. Immunohistochemical analysis revealed that genistein suppressed the in vivo lipopolysaccharide (LPS)-induced arterial endothelial fractalkine expression in the heart, kidney, and small intestine. These results suggest that genistein may provide a new pharmacological approach for suppressing fractalkine/CX3CR1-mediated injury under vascular inflammatory conditions.
 | Ask the Experts
The authors of this publication (Sung et. al) will be invited to respond to your question on this site,
and the topic will be open to discussion in the AbstractBoard.com community. | |
|
Questions about this Abstract
No questions found
Genistein suppression of TNF-alpha-induced fractalkine expression in endothelial cells.
